The fundamental obstacle to producing gene therapies for cancer is that no vector exists that can carry a particular gene to a corresponding cancer-speciˆc site. In human solid tumors, the oxygen partial pressure is lower than in normal tissue. 1, 2) Certain species of anaerobic bacteria, including Clostridium and Bidobacterium, can selectively germinate and grow in the hypoxic regions of solid tumors after intravenous injection. [3] [4] [5] [6] Biˆdobacterium longum is one of nonpathogenic anaerobic bacterium among normal bacterial ‰ora and it is found in the lower small intestine and large intestine.
Enzyme W pro-drug therapies for cancer convert nonpathogenic precursors into material with antitumor properties generated by an enzyme in the tumor. If the optional gene could be expressed in B. longum, it would be possible to use this species for enzyme W pro-drug therapy. Recently, an Escherichia coli-B. longum shuttle vector, pBLES100, was constructed. 7) Yazawa et al. reported that B. longum transfected by this shuttle vector expressed the antibiotic resistance gene via a plasmid into solid tumors. 8, 9) We have also observed that the HU gene, which encodes a histone-like protein, was expressed by B. longum at high rates. 10) We constructed a plasmid (pBLES100-S-eCD), which included the HU gene promoter and the gene encoding the cytosine deaminase of E. coli in the pBLES100 vector; the cytosine deaminase enzyme converts 5-‰uorocytosine (5-FC) to 5-‰uorouracil (5-FU). Toˆnd whether or not transfected B. longum produced active cytosine deaminase (CD), we measured the 5-FU concentration in vitro.
Materials and Methods
Bacteria. B. longum 105-A, obtained from Mitsuoka, was anaerobically cultured at 379 C to middle log phase in a slightly modiˆed Briggs broth 11, 12) using 2z lactose instead of glucose.
Plasmid construction. The plasmid was constructed as follows (Fig. 1) . (1) The gene encoding the cytosine deaminase of E. coli (eCD) was ampliˆed from pAdex1CACD (RIKEN; (Institute of Physical and Chemical Research), Gene Bank, RDB No. 1591) including the CD gene of E. coli. PCR was done using the following primers: sense primer 5?-GGTTCG-AATAACGCTTTA-3? and antisense primer 5?-CG-GTTAACTCAACGTTTGTAATC-3?. The sense primer includes an NspV site and the antisense primer includes an HpaI site. PCR was done with 125 ng of pAdex1CACD in a 40-ml reaction, 2 units of Pfu Turbo DNA polymerase, and reaction kits 2363 Cloned Gene Expression of Transfected B. longum (Strategene Cloning Systems, La Jolla, CA), according to the manufacturer's instructions. The PCR prole was as follows: 949 C for 1 min followed by 30 cycles (each cycle: 949 C for 1 min, 559 C for 1 min, 729 C for 1 min). The PCR product was cloned in pCR-BluntII-TOPO (Invitrogen, Carlsbad, CA), thus creating pCR-BluntII-TOPO-eCD. ( 2) The pCR-BluntII-TOPO-eCD was digested with NspV W HpaI, and was ligated to pBLHU15 13) and then digested with NspV W HpaI. Ligation was done with 948 ng of digested pCR-BluntII-TOPO-eCD and 546 ng of digested pBLHU15 in a 20-ml reaction mixture, 2 units of T4 DNA Ligase, and reaction kits (Promega, Madison, WI). (3) The ligation product was used to transform competent E. coli JM109 (Takara, Tokyo), according to the manufacturer's instructions. And plasmid minipreps were made by the modiˆed alkaline lysis procedure with RPM-AFS (BIO 101, Vista, CA). This plasmid was digested with HindIII, and the fragment including the CD gene was inserted. (4) The shuttle vector pBLES100 was digested with HindIII, then digested with 1.2 units of alkaline phosphatase ( E. coli C75 (Takara)), to prevent self-ligation. The product of these reactions was used as the vector. (5) Seventy-two nanograms of vector and 199.5 ng of insert were ligated in a 20-ml reaction with 2 units of T4 DNA Ligase and reaction kits (Promega). The ligation product was pBLES100-SeCD, which contained both the HU promoter and the CD encoding gene.
Polymerase chain reaction. PCR was done using 10 ng of pBLES100-S-eCD or pBLES100 in a 25-ml reaction, 0.5 units of Ampli Taq DNA polymerase, and reaction kits (Perkin Elmer W Cetus, Wellesley, MA), according to the manufacturer's instructions. The PCR proˆle was as follows: 949 C for 5 min followed by 30 cycles (each cycle: 949 C for 30 s, 559 C for 30 s, 729 C for 30 s) and aˆnal extension at 729 C for 1 min. The following primers were used for the ampliˆcation of the CD gene speciˆc sequence: sense primer 5?-GGTTCGAATAACGCTTTA-3? and antisense primer 5?-CGGTTAACTCAACGTTTGT-AATC-3?.
Transformation of pBLES100-S-eCD. The pBLES100-S-eCD was transferred directly into B. longum 105-A by electroporation with a Gene Pulser apparatus (Bio-Rad Laboratories, Hercules, CA; inter-electrode distance, 0.2 cm). Electroporation was done at 2.0 kV and a 25-mF capacitor setting with the pulse controller set at 200 Q parallel resistance, yielding a pulse duration of 4.1-4.5 ms. Stable transformants were obtained with an e‹ciency of 1.6×10 4 transformants W mg DNA under optimum conditions. Transfected B. longum was grown under anaerobic conditions at 379 C in Briggs broth containing 75 mg W ml spectinomycin.
Protein extract and western blotting. The B. longum culture solution was centrifuged (3,000×g for 
2364
T. NAKAMURA et al.
30 min at 49 C). Harvested B. longum (1.7×10 9 ) was solubilized in lysis buŠer (10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (pH 8.0), 2z glycerol, 40 mM NaCl, 1 mM imidazole, 0.4 mM b-mercaptoethanol, and 0.2 mM phenylmethylsulfonyl ‰uoride). This mixture was crushed by ultrasonic waves (1 min at 09 C). One hundred microliters was taken from this mixture, and an equivalent of 8 M urea was added. The mixture was then thoroughly stirred. In addition, a 200-ml sample buŠer (100 mM Tris-HCl (pH 6.8), 4z SDS, 20z glycerol, and 1.7 M b-mercaptoethanol) was added to this mixture. After incubation for 10 min at 959 C, samples were separated by SDS-PAGE (Amersham Pharmacia Biotech, Buckinghamshire) and transferred onto a Sequi-Blot polyvinylidene di‰uoride membrane (Bio-Rad Laboratories). The membrane was incubated in blocking buŠer (3z skim milk, and 3z bovine serum albumin in phosphate-buŠered saline (")). Blots were incubated overnight at 49 C with the primary antibodies (rabbit monoclonal anti-cytosine deaminase (Sawady Technology, Tokyo)). Blots were then washed with washing buŠer containing 0.1z Tween 20 (Bio-Rad Laboratories), and were incubated with horseradish peroxidase-conjugated (Amersham Pharmacia) anti-rabbit immunoglobulin G (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) as the secondary antibody. Blots were analyzed with the ECL western blotting detection system (Amersham Pharmacia). 
Results

Polymerase Chain Reaction
The 1300-bp DNA fragment of the CD gene was ampliˆed using pBLES100-S-eCD as the template (Fig. 2) . These results conˆrmed that the CD gene was cloned in the plasmid pBLES100-S-eCD.
Western blotting
To conˆrm whether or not the transfected B. longum produced CD, proteins extracted from wild-type B. longum and transfected B. longum were analyzed by western blotting. The molecular mass of recombinant CD was 47.5 kDa, and the transfected B. longum had the same molecular mass in all lanes. In contrast, wild-type B. longum did not have a band of 47.5 kDa (Fig. 3) . Moreover, theˆnding suggests that the CD gene was expressed and that CD was produced.
Conversion of 5-FC into 5-FU time-dependently
Twenty-ˆve milligrams of 5-FC was added to both culture solutions of wild-type and transfected B. lon- , 10 7 , and 10 8 cfu W ml. 5-FC was added to the culture medium. With transfected B. longum (), the 5-FU concentration was higher with more cells, after a certain point. With wildtype B. longum ($), 5-FU was not detected, whatever the cell density.
gum. Theˆnal concentration of wild-type and transfected B. longum was 1.4×10 8 cfu W ml each, and the 5-FC concentration was 6.25 mg W ml. The 5-FU concentration of the culture solution was measured by HPLC time-dependently. In transfected B. longum, the 5-FU concentration rose with the passage of time. However, in wild-type B. longum, 5-FU was hardly detected, even after time had passed. After the 18-hours mark, the 5-FU concentration of transfected B. longum was about 2,500 mg W ml. A signiˆcantly higher concentration of 5-FU was detected in the transfected B. longum than in the wild-type B. longum. ( pº0.001)
Conversion of 5-FC into 5-FU and the density of bacilli
Twenty-ˆve milligrams of 5-FC was added to both wild-type and transfected B. longum culture solutions. The total amount of culture solution was 6 ml, and theˆnal 5-FC concentration was 6.25 mg W ml. The number of B. longum was adjusted at each concentration: 1.0×10 3 , 1.0×10 4 , 1.0×10 5 , 1.0×10 6 , 1.0×10 7 , and 1.0×10 8 cfu W ml. After 5 h, the concentration of 5-FU in each culture solution was measured by HPLC. The observed 5-FU concentrations rose with increases in the number of the bacilli. In wild-type B. longum, 5-FU was hardly detected, even when the number of bacilli increased (Fig. 4) . The concentration of 5-FU increased in proportion to the number of B. longum.
Discussion
In this study, we conˆrmed that B. longum transfected by pBLES100-S-eCD was able to produce CD. The CD was able to convert 5-FC into 5-FU in vitro, and therefore had enzymatic activity. In addition, the 5-FU concentration increased in proportion to the number of bacilli and the amount of time that had passed.
The treatment of solid tumors by systemic administration of 5-FU has some disadvantages. First, it is necessary to administer large doses of 5-FU to the whole body to distribute a su‹ciently dense concentration of 5-FU to the tumor. Second, various side eŠects accompany massive doses of 5-FU. Five‰uorocytosine is a pro-drug with lower toxicity than that of 5-FU, and therefore it is possible to administer larger doses of 5-FC. If CD, which converts 5-FC into 5-FU, exists only in the tumor, it might be possible to obtain high-density administration of 5-FU without simultaneously distributing 5-FU among normal tissues. We refer to this manner of administration as enzyme W pro-drug therapy.
Some bacterial vectors for cancer gene therapy have been reported. In such cases, bacteria proliferate between tumor cells, and thus the therapeutic gene is not introduced into the tumor cell, but rather the therapeutic protein is produced in the tumor. This mechanism diŠerentiates enzyme W pro-drug therapy from what is called gene therapy, which uses virus and liposome vectors. Candidate bacterial vectors for gene introduction include species of Biˆdobacterium, Clostridium, and Salmonella. [3] [4] [5] [6] 14) Engineered Clostridium acetobutylicum has been reported as particularly useful for enzyme W pro-drug therapy. 15) However, Clostridium and Salmonella are pathogenic, and exothermic reactions related to oral administration have been reported. 16, 17) In contrast, Biˆdobacterium is part of the normal bacterial ‰ora in the intestine, and more importantly, it is nonpathogenic. In addition, Biˆdobacterium has been reported to suppress carcinogenesis 18) and it also can defend the host against viral infection.
19) Yazawa et al. reported that B. longum accumulated after systemic administration, and that the gene on the plasmid was expressed in the tumor. 8, 9) Therefore, it appears that B. longum, transfected by pBLES100-SeCD, proliferates in a tumor-speciˆc manner. Furthermore, if a su‹cient number of B. longum cells are present in a tumor, then 5-FC is converted into 5-FU during tumor division after systemic administration of 5-FC, and antitumor eŠects are expected from such treatments.
Theseˆndings suggest that B. longum is an excellent gene delivery system and candidate for enzyme W pro-drug therapy. B. longum promises to be useful for the treatment of hypoxic solid tumors.
